PACS Group Lifts 2026 EBITDA Outlook by $35M at Midpoint
PACS has more than doubled off its 52-week low of $7.5.
Summary
PACS Group raised its 2026 adjusted EBITDA guidance to $640M–$660M, up from $605M–$625M — a $35M midpoint increase. The company also raised its 2026 revenue outlook to $5.75B–$5.85B. This follows strong Q1 results, a $250M buyback authorization announced in May, and the June deal to acquire 34 skilled nursing facilities. The raise signals confidence in integrating those 3,633 beds and improving operational performance. In Q2, the company reported a revenue beat driven by higher occupancy, further supporting the positive trajectory. With a $7.1B market cap, the magnitude is material and likely to drive upward estimate revisions.
At the time of this announcement, PACS was trading at $45.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $7.50 to $48.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.